HER2 / Neu Positive Breast Cancer Management

Patients that are Her2 / Neu-positive disease and a positive lymph node will need systemic chemotherapy in combination with Her2 / Neu-directed immunotherapy.

Neoadjuvant treatment is preferred, as this can downstage the disease, making her a candidate for lumpectomy and targeted axillary node dissection rather than conventional axillary node dissection.

The patient will need systemic chemotherapy in the form of docetaxel /carboplatin or adriamycin / cyclophosphamide in addition to Her2-directed therapies.

21-gene assay is used to predict benefit from systemic chemotherapy in women who have hormone receptor positive, Her2/neu-negative breast cancer.

References

National Comprehensive Cancer Network (NCCN) Guidelines 2017 – Breast Cancer
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14(7):609-18.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s